Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

FAM3A: a novel mitochondrial protein for the treatment of ischemic diseases

FAM3A: a novel mitochondrial protein for the treatment of ischemic diseases FAM3 metabolism-regulating signaling molecule A (FAM3A) is a mitochondrial protein belonging to the FAM3 gene family with the potential for the treatment of ischemic diseases. FAM3A promotes adenosine triphosphate (ATP) production and improves mitochondrial function by increasing ATP synthase activity and activating the protein kinase B-cyclic AMP-responsive element binding protein-forkhead box D3-ATP synthase regulatory loop, thereby reducing reactive oxygen species production and inhibiting oxidative stress-induced cell death. Additionally, FAM3A activates the nuclear factor erythroid 2-related factor 2 signaling pathway and upregulates the expression of antioxidant proteins, further enhancing the cellular oxidative defense capacity. During angiogenesis, FAM3A positively regulates vascular endothelial growth factor A and promotes endothelial cell migration, proliferation, and tube formation. FAM3A is closely related to atherosclerosis, ischemic encephalopathy, liver ischemia – reperfusion injury, myocardial ischemia, and acute kidney injury. FAM3A plays a role in the course of these diseases via multiple mechanisms, including the phosphatidylinositol 3-kinase/protein kinase B signaling pathway, effectively reducing the inflammatory response and oxidative stress, and influencing disease development. This review comprehensively examines the role of FAM3A in the pathophysiological processes of ischemic diseases across various organs. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cell Cycle Taylor & Francis

FAM3A: a novel mitochondrial protein for the treatment of ischemic diseases

Cell Cycle , Volume 24 (5-8): 15 – Apr 18, 2025
15 pages

Loading next page...
 
/lp/taylor-francis/fam3a-a-novel-mitochondrial-protein-for-the-treatment-of-ischemic-d0DumCVzb0

References (136)

Publisher
Taylor & Francis
Copyright
© 2025 Informa UK Limited, trading as Taylor & Francis Group
ISSN
1538-4101
eISSN
1551-4005
DOI
10.1080/15384101.2025.2527777
Publisher site
See Article on Publisher Site

Abstract

FAM3 metabolism-regulating signaling molecule A (FAM3A) is a mitochondrial protein belonging to the FAM3 gene family with the potential for the treatment of ischemic diseases. FAM3A promotes adenosine triphosphate (ATP) production and improves mitochondrial function by increasing ATP synthase activity and activating the protein kinase B-cyclic AMP-responsive element binding protein-forkhead box D3-ATP synthase regulatory loop, thereby reducing reactive oxygen species production and inhibiting oxidative stress-induced cell death. Additionally, FAM3A activates the nuclear factor erythroid 2-related factor 2 signaling pathway and upregulates the expression of antioxidant proteins, further enhancing the cellular oxidative defense capacity. During angiogenesis, FAM3A positively regulates vascular endothelial growth factor A and promotes endothelial cell migration, proliferation, and tube formation. FAM3A is closely related to atherosclerosis, ischemic encephalopathy, liver ischemia – reperfusion injury, myocardial ischemia, and acute kidney injury. FAM3A plays a role in the course of these diseases via multiple mechanisms, including the phosphatidylinositol 3-kinase/protein kinase B signaling pathway, effectively reducing the inflammatory response and oxidative stress, and influencing disease development. This review comprehensively examines the role of FAM3A in the pathophysiological processes of ischemic diseases across various organs.

Journal

Cell CycleTaylor & Francis

Published: Apr 18, 2025

Keywords: Ischemic diseases; FAM3A; mitochondrial dysfunction

There are no references for this article.